CD8 Antibody (5F10): sc-70794
- CD8 Antibody (5F10) is a mouse monoclonal IgG1, cited in 4 publications, provided at 100 µg/ml
- raised against CD8 of human origin
- recommended for detection of CD8 of human origin by IF, IHC(P) and FCM
- available conjugated to either phycoerythrin or FITC for IF, IHC(P) and FCM
- See CD8 (32-M4): sc-1177 for CD8 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for CD8 Antibody (5F10). This work is in progress.
CD8 Antibody (5F10) is a mouse monoclonal IgG1 antibody that detects CD8 in human samples through applications such as immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). CD8 is a crucial cell surface glycoprotein that forms a heterodimer, typically existing as either an alpha-alpha or alpha-beta chain complex, and plays a vital role in the immune response by binding to class I major histocompatibility complex (MHC) molecules presented by antigen-presenting cells. This interaction is essential for the activation of T cytotoxic cells, which are responsible for directly killing infected or cancerous cells. CD8 not only enhances the recognition of antigens by the T cell receptor (TCR) but also strengthens the overall avidity of TCR-antigen interactions, thereby amplifying the immune response. CD8-expressing T cells have been implicated in maintaining low levels of HIV expression, highlighting their importance in both adaptive immunity and viral control. Anti-CD8 antibody (5F10) serves as an invaluable tool for researchers studying T cell dynamics and immune responses in various contexts.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD8 Antibody (5F10) References:
- Acylglycerol Kinase Maintains Metabolic State and Immune Responses of CD8+ T Cells. | Hu, Z., et al. 2019. Cell Metab. 30: 290-302.e5. PMID: 31204281
- Metformin keeps CD8+ T cells active and moving in NASH-HCC immunotherapy. | Lujambio, A. and Sarobe, P. 2022. J Hepatol. 77: 593-595. PMID: 35714813
- CD8+ T regulatory cells in lupus. | Singh, RP., et al. 2021. Rheumatol Immunol Res. 2: 147-156. PMID: 35880241
- KIR+CD8+ and NKG2A+CD8+ T cells are distinct innate-like populations in humans. | Choi, SJ., et al. 2023. Cell Rep. 42: 112236. PMID: 36897779
- Direct Involvement of CD8+ T Cells in Retinal Angiogenesis. | Bayless, KJ. 2023. Arterioscler Thromb Vasc Biol. 43: 537-539. PMID: 36947606
- Landscapes and mechanisms of CD8+ T cell exhaustion in gastrointestinal cancer. | Ding, JT., et al. 2023. Front Immunol. 14: 1149622. PMID: 37180158
- Strategies to reinvigorate exhausted CD8+ T cells in tumor microenvironment. | Guan, Q., et al. 2023. Front Immunol. 14: 1204363. PMID: 37398660
- Factors contributing to the potency of CD8+ T cells. | Sykulev, Y. 2023. Trends Immunol. 44: 693-700. PMID: 37558570
- CD8+ T cell targeting of tumor antigens presented by HLA-E. | Iyer, RF., et al. 2024. Sci Adv. 10: eadm7515. PMID: 38728394
- Phenotypic and spatial heterogeneity of CD8+ tumour infiltrating lymphocytes. | Sun, Y., et al. 2024. Mol Cancer. 23: 193. PMID: 39251981
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD8 Antibody (5F10) | sc-70794 | 100 µg/ml | $322.00 | |||
CD8 Antibody (5F10) FITC | sc-70794 FITC | 100 tests in 2 ml | $336.00 | |||
CD8 Antibody (5F10) PE | sc-70794 PE | 100 tests in 2 ml | $349.00 |